Results 281 to 290 of about 765,314 (335)

Targeting the Tumor Microbiota in Cancer Therapy Basing on Nanomaterials

Exploration, EarlyView.
Intra‐tumoral microbiota, which is a potential component of the tumor microenvironment, has been emerging as a key participant and driving factor in cancer. This article reviews the latest progress in this field, including the microbial community within tumors and its pro‐cancer mechanisms, as well as the anti‐tumor strategies targeting intra‐tumoral ...
Yanan Niu, Junya Feng, Jie Ma, Tixian Xiao, Wei Yuan   +4 more
wiley   +1 more source

Postoperative adjuvant chemoradiotherapy versus postoperative adjuvant radiotherapy for head and neck squamous cell carcinoma with adverse pathology: a systematic review and meta-analysis. [PDF]

Braz J Otorhinolaryngol
Korczaguin GG, Teixeira GV, Shaha A.
europepmc   +1 more source

Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20‐17/KM23 trial

Cancer Communications, EarlyView.
Kyoungmin Lee, Kyung‐Hun Lee, Dong‐Wan Kim, Jeesun Yoon, Yoon Ji Choi, Soohyeon Lee, Ju Won Kim, Kyong Hwa Park, Wonyoung Choi, Youngjoo Lee, Hyewon Ryu, Dong‐Hoe Koo, YunGyoo Lee, Hei‐Cheul Jeung, Min‐Young Lee, Namsu Lee, Myoung Joo Kang, Jieun Lee, Sook Hee Hong, Eun Joo Kang, In Hae Park   +20 more
wiley   +1 more source

Natural Products Targeting Protein Disulfide Isomerases: New Frontiers for Diabetes, Cancer, and Coagulation

Food Frontiers, EarlyView.
PDIA4 is significantly upregulated in response to nutrient overload in pancreatic β‐cells, resulting in aberrant ROS production, β‐cell failure, and diabetes. PDIA4 facilitates cancer development by inhibiting caspase‐mediatedcell death in cancer and promoting VEGF‐mediated protumoral immunity andangiogenesis in the tumor microenvironment, highlighting
Yi‐San Lee, Catherine Ortega, Tien‐Fen Kuo, Greta Yang, Wen‐Chin Yang   +4 more
wiley   +1 more source

Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross‐over pharmacokinetic drug‐drug interaction study

Cancer Communications, EarlyView.
Niels Heersche, Daan A. C. Lanser, Esther Oomen‐de Hoop, Attila Içli, Peter de Bruijn, Marthe S. Paats, Elisabeth F. C. van Rossum, Stijn L. W. Koolen, Ron H. N. van Schaik, Anne‐Marie C. Dingemans, G. D. Marijn Veerman, Ron H. J. Mathijssen   +11 more
wiley   +1 more source

Evaluating the Efficacy of Adjuvant Radiotherapy in the Management of Advanced Oral Cancer Cases.

J Pharm Bioallied Sci
Thakkar R, Nalini MR, Jha RK, Chaturvedi M, Prathigudupu RS, Hemavathy S, Dayanithi BS.   +6 more
europepmc   +1 more source

Exploring the feasibility of preoperative tumor-bed boost, oncoplastic surgery, and adjuvant radiotherapy schedule in early-stage breast cancer: a phase II clinical trial. [PDF]

Int J Surg
Dong H, Jing H, Wang XY, Kong XY, Wang YP, Zhai YR, Che SN, Fang Y, Wang SL, Wang J.   +9 more
europepmc   +1 more source

Incidental dose distribution to contralateral internal mammary nodes in breast cancer patients undergoing adjuvant radiotherapy. [PDF]

Clin Transl Radiat Oncol
Behzadi ST, Duesberg M, Moser R, Duma MN, Oechsner M, Kiesl S, Nano J, Combs SE, Borm KJ.   +8 more
europepmc   +1 more source

The use of biodegradable temporising matrix (BTM) for facial unit reconstruction with adjuvant radiotherapy-A case study. [PDF]

JPRAS Open
Buick TA, Pathak AM, Jordan DJ.
europepmc   +1 more source

Recommended optimal range for the count of examined lymph nodes and lymph node ratio for postoperative adjuvant radiotherapy in patients with pN2 non-small cell lung cancer: a multicenter retrospective cohort investigation. [PDF]

J Thorac Dis
Huang Q, Weng X, Hu Y, Li Z, Wu L, Hu Z, Yu D, Xiong L.   +7 more
europepmc   +1 more source